<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZINGO- lidocaine hydrochlorideÂ powderÂ </strong><br>Medline Industries, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Zingoâ„¢ safely and effectively. See full prescribing information for Zingoâ„¢.  Zingoâ„¢ (lidocaine hydrochloride monohydrate) <br>powder intradermal injection system <br>Initial U.S. Approval: 1948  </div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>Zingoâ„¢Â  is an amide local anesthetic indicated for use on intact skin to provide local <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> prior to venipuncture or peripheral intravenous cannulation in children 3â€“18 years of age.Â (<a href="#_1_Indications_and">1</a>)</dd>
<dt>â€¢</dt>
<dd>Zingoâ„¢ is indicated for use on intact skin to provide topical local <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> prior to venipuncture in adults. (<a href="#_1_Indications_and">1</a>) </dd>
</dl>
<p class="Highlighta">Important Limitations: </p>
<dl>
<dt>â€¢</dt>
<dd>For use on intact skin only (<a href="#_1_Indications_and">1</a>,<a href="#_2_Dosage_and">2</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>For external use only (<a href="#_5_Warnings_and">5</a>)</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Apply one Zingoâ„¢ (0.5 mg lidocaine hydrochloride monohydrate) to the site planned for venipuncture or intravenous cannulation, one to three minutes prior to needle insertion. (<a href="#ID_614ec663-ade2-48c4-a3a2-33ec317f6dd5">2.1</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>Perform the procedure within 10 minutes after Zingoâ„¢ administration. (<a href="#_2_Dosage_and">2</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>Use Zingoâ„¢ only on intact skin. (<a href="#_2_Dosage_and">2</a>)</dd>
</dl></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Zingoâ„¢ is a sterile, single-use,Â powderÂ intradermal injectionÂ system containing 0.5Â mg lidocaine hydrochloride monohydrate. (<a href="#_3_Dosage_Forms">3</a>) Â Zingoâ„¢ utilizes a helium-powered delivery system. (<a href="#_11_Description">11</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Zingoâ„¢ is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. (<a href="#_4_Contraindications">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Use on intact skin only (<a href="#ID_614ec663-ade2-48c4-a3a2-33ec317f6dd5">2.1</a>, <a href="#_5_Warnings_and">5</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>Avoid contact with the eye (<a href="#ID_614ec663-ade2-48c4-a3a2-33ec317f6dd5">2.1</a>, <a href="#_5_Warnings_and">5</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>Do not use if device is dropped or the pouch is damaged or tornÂ (<a href="#ID_614ec663-ade2-48c4-a3a2-33ec317f6dd5">2.1</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>Patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or <span class="product-label-link" type="condition" conceptid="4332151" conceptname="Platelet disorder">platelet disorders</span> could have a higher risk of superficial dermal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#_5_Warnings_and">5</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (&gt;5%) areÂ <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> at the site of administration: <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.Â (<a href="#_6_1_Clinical_Trials">6.1</a>) </p>
<p class="Highlighta">Â  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Marathon Pharmaceuticals, LLC, at 1-866-562-4620 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span> </p>
<p class="Highlighta"><span class="Bold">See 17 for PATIENT COUNSELING INFORMATION. 	 </span> </p>
</div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 11/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1Â Â Â Â Â  	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2Â Â Â Â Â  	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Instructions for Use</a></h2>
<h1><a href="#section-3" class="toc">3Â Â Â Â Â  	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4Â Â Â Â Â  	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5Â Â Â Â Â  	WARNINGS AND PRECAUTIONS</a></h1>
<h1><a href="#section-6" class="toc">6Â Â Â Â Â  	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1Â Â Â Â Â  	Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">8Â Â Â Â Â  	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1Â Â Â Â Â  	Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.2Â Â Â Â Â  	Labor and Delivery</a></h2>
<h2><a href="#section-7.3" class="toc">8.3Â Â Â Â Â  	Nursing Mothers</a></h2>
<h2><a href="#section-7.4" class="toc">8.4Â Â Â Â Â  	Pediatric Use</a></h2>
<h2><a href="#section-7.5" class="toc">8.5Â Â Â Â Â  	Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">9Â Â Â Â Â  	DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h1><a href="#section-9" class="toc">10Â Â Â Â Â  	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11Â Â Â Â Â  	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12Â Â Â Â Â  	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1Â Â Â Â Â  	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2Â Â Â Â Â  	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3Â Â Â Â Â  	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13Â Â Â Â Â  	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1Â Â Â Â Â  	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14Â Â Â Â Â  	CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16Â Â Â Â Â  	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17Â Â Â Â Â  	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="_1_Indications_and"></a><a name="section-1"></a><p></p>
<h1>1Â Â Â Â Â  	INDICATIONS AND USAGE</h1>
<p class="First">Zingoâ„¢ is indicated for use on intact skin to provide topical local <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> prior to venipuncture or peripheral intravenous cannulation, in children 3â€“18 years of age. </p>
<p>Zingoâ„¢ is indicated for use on intact skin to provide topical local <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> prior to venipuncture in adults. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_2_Dosage_and"></a><a name="section-2"></a><p></p>
<h1>2Â Â Â Â Â  	DOSAGE AND ADMINISTRATION</h1>
<p class="First">Apply one Zingoâ„¢Â (0.5 mg lidocaine hydrochloride monohydrate) to the site planned for venipuncture or intravenous cannulation, one to three minutes prior to needle insertion.</p>
<p>Perform the procedure within 10 minutes after Zingoâ„¢ administration.</p>
<p>Use Zingoâ„¢ only on intact skin.</p>
<p>Application of one additional Zingoâ„¢ at a new location is acceptable after a failed attempt at venous access.  Multiple administrations of Zingoâ„¢ at the same location are not recommended.</p>
<p>When Zingoâ„¢ is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all sources should be considered, as local anesthetics are thought to have at least additive toxicities.</p>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_614ec663-ade2-48c4-a3a2-33ec317f6dd5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Instructions for Use</h2>
<table>
<col width="81%">
<col width="34%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">
<p class="First"><span class="Underline">Prepare the Treatment Site and Device</span>: </p>
<p>Examine the treatment site to ensure that the skin is intact. Clean the site, according to standard practice.<br><br>Visually inspect the pouch. DoÂ not use if the pouch has been torn, or damaged or if the device has been dropped.<br><br>Tear open the pouch using the notch provided (FigureÂ 1a). Remove Zingoâ„¢ from the pouch, being careful not to touch the purple outlet (open end) to avoid contamination (FigureÂ 1b).</p>
</td>
<td class="Botrule Lrule Rrule Toprule">
<p class="First"><span class="Bold">Figure 1a</span></p>
<span class="Bold"><a name="id1985265252"></a><img alt="Figure 1a - Tear at notches" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-12.jpg"></span><span class="Bold">Figure 1b</span><span class="Bold"><a name="id1985265256"></a><img alt="Figure 1b - Hold Zingo being careful not to touch the purple outlet " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-11.jpg"></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Position Zingoâ„¢: Grip Zingoâ„¢ and place on the application site, with one hand, as illustrated in FigureÂ 2, or with both hands, as shown in Figure 3.</p></td>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Figure 2</p>
<a name="id1985265280"></a><img alt="Figure 2 - Grip Zingoâ„¢ and place on the application site, with one hand" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-10.jpg"><p>Figure 3</p>
<a name="id1985265288"></a><img alt="Figure 3 - Grip Zingoâ„¢ and place on the application site" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-09.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Ensure that the patientâ€™s treatment site is supported to prevent movement. Seal the purple Zingoâ„¢ outlet against the patientâ€™s skin. Hold the device perpendicular to the skin, making sure that your thumb can reach the green start button.<br><br>Avoid gaps between the skin and the Zingoâ„¢ outlet, like the one illustrated in FigureÂ 4, as gaps will impede drug delivery.</p></td>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Figure 4</p>
<a name="id1985265343"></a><img alt="Figure 4 - Avoid gaps" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-08.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Release the Safety Interlock: Apply adequate downward pressure to release the safety interlock, while maintaining the seal between Zingoâ„¢ and the skin.<br><br>Zingoâ„¢ is ready for administration when the green start button has moved into the upward position, as illustrated in FigureÂ 5a.</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Figure 5a<a name="id1985265367"></a><img alt="Figure 5a - Seal outlet against skin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-07.jpg"></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2">
<p class="First">Zingoâ„¢ cannot be actuated without releasing the internal safety interlock, as illustrated in Figure 5b.</p>
<p>Figure 5b.</p>
<a name="id1985265395"></a><img alt="Figure 5b -Zingoâ„¢ cannot be actuated without releasing the internal safety interlock" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-06.jpg">
</td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Administer Zingoâ„¢: While maintaining downward pressure, administer the dose by pressing the green start button, as illustrated in FigureÂ 6. DoÂ not move Zingoâ„¢ during administration. Actuation is accompanied by a â€œpoppingâ€? sound, indicating that the dose has been discharged.</p></td>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Figure 6</p>
<a name="id1985265451"></a><img alt="Figure 6 - Push button inward" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-05.jpg">
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"><p class="First">Remove Zingoâ„¢: Remove Zingo from the application site and dispose.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="2"><p class="First">Begin Procedure: Start the venipuncture or intravenous cannulation procedure 1â€“3Â minutes after Zingoâ„¢ administration.Â </p></td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="_3_Dosage_Forms"></a><a name="section-3"></a><p></p>
<h1>3Â Â Â Â Â  	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Zingoâ„¢Â (lidocaine hydrochloride monohydrate)Â powder intradermal injectionÂ system<span class="Bold">Â </span>contains 0.5 mg of sterile lidocaine hydrochloride monohydrate.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="_4_Contraindications"></a><a name="section-4"></a><p></p>
<h1>4Â Â Â Â Â  	CONTRAINDICATIONS</h1>
<p class="First">Zingoâ„¢ is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_5_Warnings_and"></a><a name="section-5"></a><p></p>
<h1>5Â Â Â Â Â  	WARNINGS AND PRECAUTIONS</h1>
<p class="First">Do not use around the eyes.</p>
<p>Do not use Zingoâ„¢ on body orifices, mucous membranes, or on areas with a compromised skin barrier.  Only useÂ Zingoâ„¢ on skin locations where an adequate seal can be maintained.</p>
<p>Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> or <span class="product-label-link" type="condition" conceptid="4101133" conceptname="Pseudocholinesterase deficiency">pseudocholinesterase deficiency</span>, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations of lidocaine.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or <span class="product-label-link" type="condition" conceptid="4332151" conceptname="Platelet disorder">platelet disorders</span> could have a higher risk of superficial dermal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_7d23d043-f7e8-4500-9444-b71684549c94"></a><a name="section-6"></a><p></p>
<h1>6Â Â Â Â Â  	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_6_1_Clinical_Trials"></a><a name="section-6.1"></a><p></p>
<h2>6.1Â Â Â Â Â  	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The safety of Zingoâ„¢ has been evaluated in 10 clinical trials, five in adults and five in pediatric patients. </p>
<p>The five adult clinical trials consisted of a randomized, double-blind, parallel-arm, sham-placebo controlled Phase 3 trial that enrolled 693 patients, two randomized, double-blind, crossover design, sham-placebo controlled Phase 1 trials that enrolled 455 patients, and two open-label studies that enrolled 44 patients. A total of 742 adults received an active treatment with an active treatment that delivered a 0.5 mg dose of lidocaine, while 775 received placebo. </p>
<p>The five pediatric clinical trials consisted of five randomized, double-blind, parallel-arm, sham-placebo controlled trials in which 1761 patients, ages 3 to 18, received either Zingoâ„¢ or a sham placebo device. A total of 906 pediatric patients received active treatment, while 855 received placebo. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reaction</span></span></p>
<p>The application site was specifically assessed for four categories of skin site reaction (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>). </p>
<p>In adults, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> occurred in 67.3% of Zingoâ„¢-treated patients, and in 25.0% of placebo-treated patients. <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span> occurred in 46.4% of Zingoâ„¢-treated patients, and in 7.0% of placebo-treated patients. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> occurred in 4.3% of Zingoâ„¢-treated patients, and in 0.8% of placebo-treated patients. <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> occurred in 9.4% of Zingoâ„¢-treated patients and in 6.2% of placebo-treated patients. </p>
<p>In pediatric patients, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> occurred in 53% of Zingo-treated patients, and in 27% of placebo-treated patients. <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span> occurred in 44% of Zingo-treated patients, and in 5% of placebo-treated patients. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> occurred in 8% of Zingo-treated patients, and in 3% of placebo-treated patients. <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> occurred in 1% of patients in both treatment groups. </p>
<p><span class="Italics">Adverse Reactions</span></p>
<p>Amongst the 742 adult patients receiving active treatment and 775 adult patients receiving sham placebo treatment in the 5 adult studies, the percentage of adult patients with any adverse reactions was 3.9% in the active-treated patients and 4.9% in the sham placebo treated patients. </p>
<p>Most adverse reactions were application-site related (i.e., <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoaesthesia</span> (0% active, 0.5% sham placebo), burning (0.54% active, 0.4% sham placebo), and venipuncture site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (0.4% active, 1.7% sham placebo)). </p>
<p>The most common systemic adverse reaction was <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, which occurred in 0.9% of active-treated adult patients and in 0.7% of sham placebo treated adult patients. No other systemic adverse events occurred in more than two patients in either treatment group. </p>
<p>Amongst the 906 pediatric patients receiving active treatment and 855 pediatric patients receiving sham placebo treatment, the percentage of pediatric patients with any adverse reactions was approximately 9% in each treatment group. </p>
<p>Most adverse reactions were application-site related (i.e., <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>), occurring in 4% of pediatric patients in each treatment group. </p>
<p>The most common systemic adverse reactions were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2%) and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1%).</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_779c75d9-9e47-4300-ade6-172926f8ece0"></a><a name="section-7"></a><p></p>
<h1>8Â Â Â Â Â  	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_1ed021c3-199b-4783-a019-77736c932fe8"></a><a name="section-7.1"></a><p></p>
<h2>8.1Â Â Â Â Â  	Pregnancy</h2>
<p class="First">Zingoâ„¢ was not formally evaluated for effects on reproduction.  Significant systemic exposure to lidocaine is not expected under recommended conditions of use of Zingoâ„¢ as lidocaine levels were below the limit of detection in human studies.  LidocaineÂ has been previously tested for reproductive toxicity in animal studies, however.  The following ratios are based on the assumption that the applied dose is completely absorbed through the skin.</p>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_2cd9f65c-7f11-4277-9d1c-57f21318415a"></a><a name="section-7.1.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<p class="First">Pregnancy Category B.  Lidocaine was not teratogenic in rats given subcutaneous doses up to 60 mg/kg [360 mg/m<span class="Sup">2</span> or 1200-fold the single dermal administration (SDA) of 0.5Â mg lidocaine in a 60 kg individual (0.3 mg/m<span class="Sup">2</span>)] or in rabbits up to 15 mg/kg (180 mg/m<span class="Sup">2</span> or 600-fold the SDA).  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, Zingoâ„¢ should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="ID_bd361265-52e0-4e9a-85dd-5c1978736e6a"></a><a name="section-7.1.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Lidocaine, containing 1:100,000 epinephrine, at a dose of 6 mg/kg (36 mg/m<span class="Sup">2</span> or 120-foldÂ the SDA) injected into the masseter muscle of the jaw or into the gum of the lower jaw of Long-Evans hooded pregnant rats on gestation day 11 led to <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> in neonatal behavior among offspring.  <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">Developmental delays</span> were observed for negative geotaxis, static righting reflex, visual discrimination response, sensitivity and response to thermal and electrical <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> stimuli, and water maze acquisition.  The <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> of the neonatal animals were transient with responses becoming comparable to untreated animals later in life.  The clinical relevance of the animal data is uncertain.  No adequate and wellâ€“controlled studies have been conducted in pregnant women.  Because animal studies are not always predictive of human response, Zingoâ„¢ should be used during pregnancy only if the potential benefit justifies risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID_e4076919-61c8-4440-aa81-7342a4319d0e"></a><a name="section-7.2"></a><p></p>
<h2>8.2Â Â Â Â Â  	Labor and Delivery</h2>
<p class="First">Lidocaine is not contraindicated in labor and delivery.  In humans, the use of lidocaine for labor conduction <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> has not been associated with an increased incidence of adverse fetal effects either during delivery or during the neonatal period.  Should Zingoâ„¢ be used concomitantly with other products containing lidocaine, total doses contributed by all formulations must be considered.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_80a896e6-f3fe-4b1d-8995-f95cecd548a0"></a><a name="section-7.3"></a><p></p>
<h2>8.3Â Â Â Â Â  	Nursing Mothers</h2>
<p class="First">Lidocaine is excreted into human milk; therefore, caution should be exercised when Zingoâ„¢Â is administered to a nursing mother.  BecauseÂ noÂ plasma concentrations of lidocaine are detected after topical administration of Zingoâ„¢ in recommended doses, the small amount of lidocaine that would be ingested orally by a suckling infant is unlikely to cause adverse effects. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_d54fd21e-71af-4706-ab6d-affa5c35cafb"></a><a name="section-7.4"></a><p></p>
<h2>8.4Â Â Â Â Â  	Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age ofÂ 3 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_8ba8c71b-2326-4541-b38d-fcba6d446b0a"></a><a name="section-7.5"></a><p></p>
<h2>8.5Â Â Â Â Â  	Geriatric Use</h2>
<p class="First">Of the 693 patients evaluated in a Phase 3 randomized, double blind, sham-placebo-controlled trial in adults, 17% were of 65 and over. The safety and effectiveness of Zingoâ„¢ in geriatric patients were similar to that of Zingoâ„¢ in adults under 65 years of age</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="ID_813fe24a-e059-4363-96a0-d4926f566430"></a><a name="section-8"></a><p></p>
<h1>9Â Â Â Â Â  	DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Zingoâ„¢ is not known to possess drug abuse or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> potential.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_7fb78d83-9425-49b2-a953-51bdb49babce"></a><a name="section-9"></a><p></p>
<h1>10Â Â Â Â Â  	OVERDOSAGE</h1>
<p class="First">In adults following a single administration of Zingoâ„¢ the plasma levels of lidocaine were below the limit of detection (5 ng/mL).  Signs of central nervous system (CNS) toxicity may start at plasma concentrations of lidocaine as low as 1000 ng/mL, and the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> generally increases with increasing plasma levels.  Very high levels of lidocaine can cause <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, decreases in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, total peripheral resistance, and mean arterial pressure, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.  The toxicity of coadministered local anesthetics is thought to be at least additive.  In the absence of massive topical <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or oral ingestion, other etiologies for the clinical effects or overdosage from other sources of lidocaine or other local anesthetics should be considered.  The management of overdosage includes close monitoring, supportive care, and symptomatic treatment.  Dialysis is of negligible value in the treatment of acute overdosage of lidocaine.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="_11_Description"></a><a name="section-10"></a><p></p>
<h1>11Â Â Â Â Â  	DESCRIPTION</h1>
<p class="First">Zingoâ„¢ (lidocaine hydrochloride monohydrate)Â powder intradermal injectionÂ systemÂ contains 0.5 mg of sterile lidocaine hydrochloride monohydrate.</p>
<p>The chemical name is 2-diethylamino-2',6'-acetoxylidide, monohydrochloride, monohydrate.  TheÂ molecular formula is C<span class="Sub">14</span>H<span class="Sub">22</span>N<span class="Sub">2</span>O Â· HCl Â· H<span class="Sub">2</span>O with a molecular weight of 288.8Â Da.  Lidocaine hydrochloride monohydrate, a local anesthetic of the amide class, has the following structural formula:Â Â </p>
<div class="Figure">
<a name="id569"></a><img alt="Figure 7 - Zingo Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=zingo-figure-09.jpg">
</div>
<p>Lidocaine hydrochloride monohydrate is freely soluble in water, soluble in alcohol and chloroform, insoluble in ether, and melts at around 74â€“79Â°C.</p>
<p>Zingoâ„¢ is a ready-to-use, sterile, single-use, disposable, needle-free delivery system.  Zingoâ„¢ consists of the following components: a drug reservoir cassette filled with 0.5Â mg lidocaine hydrochloride monohydrate as a powder with aÂ nominal particle size of 40Â Âµm, a pressurized helium gas cylinder, and a safety interlock. The safety interlock prevents inadvertent actuation of the device. Once Zingoâ„¢ is pressed against the skin, the interlock is released, allowing the button to be depressed to actuate the device. A sound similar to that of a popping balloon is emitted at the time Zingoâ„¢ is actuated.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_19b023b5-54af-4a5c-9950-10a6d53c559d"></a><a name="section-11"></a><p></p>
<h1>12Â Â Â Â Â  	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_e928fac3-145f-4443-bba2-dc9e8233a683"></a><a name="section-11.1"></a><p></p>
<h2>12.1Â Â Â Â Â  	Mechanism of Action</h2>
<p class="First">Zingoâ„¢ delivers lidocaineÂ hydrochloride monohydrate into the dermis.Â Â Lidocaine is an amide-type local anesthetic agent that blocks sodium ion channels required for the initiation and conduction of neuronal impulses, resulting in local anesthesia.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_fb0ce421-059f-42b8-92e9-31ac24ea8e88"></a><a name="section-11.2"></a><p></p>
<h2>12.2Â Â Â Â Â  	Pharmacodynamics</h2>
<p class="First">Zingoâ„¢ provides local dermal <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> within 1â€“3Â minutes of application.  <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> diminishes within 10 minutes of treatment.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_7c4e5ace-2b91-4aa2-a2bc-876e9123ac4c"></a><a name="section-11.3"></a><p></p>
<h2>12.3Â Â Â Â Â  	Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption</span></p>
<p>A singleÂ dose ofÂ Zingoâ„¢ in adultsÂ did not produce detectableÂ plasma concentrationsÂ of lidocaineÂ (limit of quantitation 5Â ng/mL) in any subject tested (n = 38).</p>
<p>Application of Zingoâ„¢ to broken or inflamed skin, or multiple Zingoâ„¢ applications,Â could result in systemic plasma levels of lidocaineÂ that could produce systemic toxicity.</p>
<p><span class="Italics">Distribution</span></p>
<p>When lidocaine is administered intravenously to healthy volunteers, the steady-state volume of distribution is approximately 0.8Â toÂ 1.3Â L/kg.  At much higher plasma concentrations (1Â toÂ 4Â mcg/mL of free base) than those found following application of Zingoâ„¢, the plasma protein binding of lidocaine is concentration dependent.  Lidocaine crosses the placental and blood brain barriers, presumably by passive diffusion.  CNS toxicity may typically be observed around 5000 ng/mLÂ of lidocaine; however a small number of patients reportedly may show signs of toxicity at approximately 1000 ng/mL. </p>
<p><span class="Italics">Metabolism</span></p>
<p>It is not known if lidocaine is metabolized in the skin.  Lidocaine is metabolized rapidly by the liver to a number of metabolites including monoethylglycinexylidide (MEGX) and glycinexylidide (GX), both of which have pharmacologic activity similar to, but less potent than that of lidocaine.  The major metabolic pathway of lidocaine, sequential N-deethylation to monoethylglycinexylidide (MEGX) andÂ glycinexylidide (GX), is primarily mediated by CYP1A2 with a minor role of CYP3A4.  The metabolite, 2,6-xylidine, has unknown pharmacologic activity.  Following intravenous administration of lidocaine, MEGX and GX concentrations inÂ serum range from 11%Â to 36% and from 5% to 11% of lidocaine concentrations, respectively.  Serum concentrations of MEGX are about one-third the serum lidocaine concentrations. </p>
<p><span class="Italics">Elimination</span></p>
<p>The half-life of lidocaine elimination from the plasma following intravenous administration is approximately 1.8 hours.  Lidocaine and its metabolites are excreted by the kidneys.  More than 98% of an absorbed dose of lidocaine can be recovered in the urine as metabolites or parent drug.  Less than 10% of lidocaine is excreted unchanged in adults, and approximately 20% is excreted unchanged in neonates.  The systemic clearance is approximately 8â€“10 mL/min/kg.  During intravenous studies, the elimination half-life of lidocaine was statistically significantly longer in elderly patients (2.5 hours) than in younger patients (1.5 hours).</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_8d1ed9b7-3b50-40d6-9966-22f85f0229a7"></a><a name="section-12"></a><p></p>
<h1>13Â Â Â Â Â  	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_0d6350c8-4456-48a3-87ed-b3389664cae9"></a><a name="section-12.1"></a><p></p>
<h2>13.1Â Â Â Â Â  	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">Carcinogenesis</span></p>
<p>Long-term studies in animals have not been performed to evaluate the carcinogenic potential of lidocaine.</p>
<p><span class="Italics">Mutagenesis</span></p>
<p>No mutagenic potential of lidocaine was demonstrated in the inÂ vitro Ames Bacterial Reverse Mutation Assay, the in vitro chromosome aberration assay using Chinese hamster ovary cells, and the inÂ vivo mouse micronucleus assay. </p>
<p><span class="Italics">Impairment of Fertility</span></p>
<p>Zingoâ„¢ was not formally evaluated for effects on fertility. Significant systemic exposure to lidocaine is not expected under recommended conditions of use of Zingoâ„¢, as lidocaine levels were below the limit of detection in human studies. Lidocaine has been previously tested in animal studies for effects on fertility, however. The following ratios are based on the assumption that the applied dose is completely absorbed through the skin.</p>
<p>Lidocaine did not affect fertility in female rats when given via continuous subcutaneous infusion via osmotic minipumps up to doses of 250 mg/kg/day [1500 mg/m<span class="Sup">2</span> or 5000-fold higher than the SDA of 0.5 mg lidocaine in a 60 kg individual (0.3 mg/m<span class="Sup">2</span>)].  Although lidocaine treatment of male rats increased the copulatory interval and led to a dose-related decreased homogenization resistant sperm head count, daily sperm production, and spermatogenic efficiency, the treatment did not affect overall fertility in male rats when given subcutaneous doses up to 60 mg/kg (360 mg/m<span class="Sup">2</span> orÂ 1200-fold the SDA).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_6b255c7a-9d83-48b4-9685-1be413822f82"></a><a name="section-13"></a><p></p>
<h1>14Â Â Â Â Â  	CLINICAL STUDIES</h1>
<p class="First"><span class="Italics">Efficacy in Adults</span></p>
<p>The efficacy of Zingoâ„¢ in adults was evaluated in a randomized, double-blind, parallel-arm, sham-placebo controlled trial in which adult patients who required a venipuncture or peripheral venous cannulation received either Zingoâ„¢ or a sham placebo device. </p>
<p>Patients were treated with Zingoâ„¢ or a placebo device at the antecubital fossa or back of the hand, between one and three minutes prior to venipuncture or peripheral venous cannulation. Measurements of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> were made immediately following the procedure. Efficacy was measured using a continuous 100 mm visual analogue scale ranging from 0 (â€œno painâ€?) to 100 (â€œworst possible painâ€?). </p>
<p>Many of the patients had chronic medical problems such as <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and over one fourth of the population may have been at higher than average risk of dermal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> due to use of concomitant medications such as NSAIDs, aspirin, and corticosteroids. </p>
<p>Treatment with active drug resulted in less <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> compared with placebo (see Table 1).</p>
<p><span class="Bold">Table 1: Visual Analogue Scale Score (Full Safety/Efficacy Population) </span></p>
<table>
<col width="18%">
<col width="18%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="middle"><p class="First">Adult Study</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Active (N = 345)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Placebo (N = 348)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Adjusted Mean, LSM<span class="Sup">1</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11.61</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16.23</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Difference in LSMs (SE<span class="Sup">2</span>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First">-4.62 (1.55)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">95% Confidence Limits</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First">-7.67, -1.57</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">1 least squares mean	2 standard error</span></p>
<p>However, efficacy was primarily seen in patients undergoing venipuncture at the antecubital fossa, while patients undergoing cannulation at the back of the hand did not demonstrate a difference between active and sham administrations.</p>
<p><span class="Italics">Efficacy in Pediatric Patients </span></p>
<p>The efficacy of Zingoâ„¢ in patients 3â€“18 years of age was evaluated in two randomized, double-blind, parallel-arm, sham-placebo controlled trials in which pediatric patients received either Zingoâ„¢ or a sham placebo device. </p>
<p>The overall patient population consisted of healthy pediatric patients as well as those with acute and chronic medical conditions (i.e., <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder, <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> and renal or hepatic transplantation) ages 3â€“18 years. All patients required peripheral venipuncture or intravenous cannulation as part of their clinical care. </p>
<p>Two efficacy trials (Studies 1 and 2) were conducted during which patients were treated with Zingoâ„¢ or a placebo device at the back of hand or antecubital fossa, between one and three minutes prior to venipuncture or peripheral venous cannulation. Measurements of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> were made immediately following the venous procedure. Efficacy was measured using a modified version of the Wong-Baker FACES <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> rating scale [a categorical 6-point scale containing 6 faces ranging from 0 (â€œno hurtâ€?) to 5 (â€œhurts worstâ€?)]. </p>
<p>In both studies, treatment with active drug resulted in less <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, from venipuncture or peripheral IV cannulation, compared with placebo (See Table 2).</p>
<p>Table 2: Modified FACES Scale Score (ITT Population), Studies 1 and 2</p>
<table>
<col width="18%">
<col width="9%">
<col width="9%">
<col width="9%">
<col width="9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="middle"><p class="First">Study 1</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="middle"><p class="First">Study 2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle">
<p class="First">Active </p>
<p>(N = 292)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="middle">
<p class="First">Placebo </p>
<p>(N = 287)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="middle">
<p class="First">Active </p>
<p>(N = 269)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="middle">
<p class="First">Placebo </p>
<p>(N = 266)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Adjusted Mean, LSM<span class="Sup">1</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.77</p></td>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="middle"><p class="First">2.10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.38</p></td>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="middle"><p class="First">1.77</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Difference in LSMs (SE<span class="Sup">2</span>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First">-0.33 (0.13)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="justify" colspan="2" valign="middle"><p class="First">-0.39 (0.13)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">95% Confidence Limits</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First">-0.58, -0.08</p></td>
<td class="Botrule Lrule Rrule Toprule" align="justify" colspan="2" valign="middle"><p class="First">-0.65, -0.13</p></td>
</tr>
</tbody>
</table>
<p>1 least squares mean2	 standard error</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_31a9e8a9-f530-4076-a782-937e3f8977c0"></a><a name="section-14"></a><p></p>
<h1>16Â Â Â Â Â  	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDCÂ 53329-200-57 Â Zingoâ„¢Â (lidocaine hydrochloride monohydrate)Â powder intradermal injectionÂ systemÂ contains 0.5Â mg of sterile lidocaine hydrochloride monohydrate. Zingoâ„¢ is a single-use device packaged in an individual foil/clear pouch placed inside aÂ bubble-wrap sleeve.  Twelve poucheddevicesÂ are placed in labeled cartons.</p>
<p>Cartons are stored at controlled room temperature (15â€“30Â°C, 59â€“86Â°F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_5fd278e8-2e31-4260-afb9-dddc103cac70"></a><a name="section-15"></a><p></p>
<h1>17Â Â Â Â Â  	PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be made aware that a soundÂ similar to that of a popping balloonÂ is emitted at the time Zingoâ„¢ isÂ actuated.</p>
<p>Patients should be informed that <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> includingÂ <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> and edemaÂ may occur.</p>
<p><br><br>Manufactured by:</p>
<p>Powder Pharmaceuticals, Inc.</p>
<p>Hong Kong, China</p>
<p>Zingoâ„¢ is a trademark of Powder</p>
<p>Pharmaceuticals, Incorporated. </p>
<p><br>Distributed by:</p>
<div class="Figure">
<a name="id449283905"></a><img alt="Medline Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-04.jpg">
</div>
<p>Medline Industries, Inc.,</p>
<p>Mundelein, IL 60060, USA (RA14)</p>
<p>REF: 53329-200-57</p>
<p>Under license by Marathon Pharmaceuticals, LLC. </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_a39cc3b7-69d3-485d-b236-3918a8f7b00e"></a><a name="section-16"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First">NDC 53329-200-57</p>
<p>Zingo â„¢ </p>
<p>(Lidocaine hydrochloride monohydrate)</p>
<p>Powder intradermal injection system 0.5mg</p>
<p><span class="Bold">RX only. </span></p>
<p>Manufactured by: Powder Pharmaaceuticals, Inc. Hong Kong, China</p>
<p>Distributed by: Medline Industries, Inc., Mundelein, IL, 60060 USA</p>
<p><span class="Bold">This is a single use product.</span> Do not use if pouch is torn or damaged or if the product has been dropped. </p>
<p>Do not use if the <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of the purple outlet has been compromised. Store at 15-30ÂºC.</p>
<p>See package insert for full prescribing information. For use on intact skin. Zingoâ„¢ should be applied by a health care practitioner. </p>
<p>CONTAINS 12 STERILE UNITS. </p>
<div class="Figure">
<a name="id449297650"></a><img alt="Zingo Principal Display Panel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_c15edd90-e35b-43d3-8efc-efcaee32793a"></a><a name="section-17"></a><p></p>
<h1>Package Label â€“ Side Panel 1</h1>
<div class="Figure">
<a name="id449295858"></a><img alt="Zingo Side Panel 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_0e4b41d7-895d-4eea-bdc2-ea78f9483d35"></a><a name="section-18"></a><p></p>
<h1>Package Label â€“ Side Panel 2</h1>
<div class="Figure">
<a name="id449295863"></a><img alt="Zingo Side Panel 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_c045a5f4-0e67-43a2-87ba-19f3c121f3e6"></a><a name="section-19"></a><p></p>
<h1>Package Label â€“ Back Panel</h1>
<div class="Figure">
<a name="id449298643"></a><img alt="Zingo Back Panel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c913688b-c51d-44c2-8ce6-5200f1ea0bab&amp;name=C913688B-C51D-44C2-8CE6-5200F1EA0BAB-00.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZINGOÂ 		
					</strong><br><span class="contentTableReg">lidocaine hydrochloride powder</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53329-200</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRADERMAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LIDOCAINE HYDROCHLORIDE</strong> (LIDOCAINE) </td>
<td class="formItem">LIDOCAINE HYDROCHLORIDE ANHYDROUS</td>
<td class="formItem">0.5Â mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53329-200-57</td>
<td class="formItem">12  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022114</td>
<td class="formItem">02/21/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Medline Industries, Inc.
							(025460908)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cbdd3282-35f3-4d0d-821c-8b61e8019798</div>
<div>Set id: c913688b-c51d-44c2-8ce6-5200f1ea0bab</div>
<div>Version: 2</div>
<div>Effective Time: 20141113</div>
</div>
</div>Â <div class="DistributorName">Medline Industries, Inc.</div></p>
</body></html>
